Antibodies to the CD40 ligand have modulated the immune system in animal experiments and in human clinical trials. Assumptions about how these antibodies work are now reexamined (pages 1275–1280).
References
Billingham, R.E., Brent, L. & Medawar, P.B. Nature 172, 603–606 (1953).
Larsen, C.P. et al. Nature 381, 434–437 (1996).
Kirk, A.D. et al. Nat. Med. 5, 686–693 (1999).
Monk, N.J. et al. Nat. Med. 9, 1275–1280 (2003).
Qin, S., Cobbold, S., Benjamin, R. & Waldmann, H. J. Exp. Med. 169, 779–794 (1989).
Kawai, T., Andrews, D., Colvin, R.B., Sachs, D.H. & Cosimi, A.B. Nat. Med. 6, 114 (2000).
Graca, L., Honey, K., Adams, E., Cobbold, S.P. & Waldmann, H. J. Immunol. 165, 4783–4786 (2000).
Durham, M.M. et al. J. Immunol. 165, 1–4 (2000).
Wells, A.D. et al. Nat. Med. 5, 1303–1307 (1999).
Iwakoshi, N.N. et al. J. Immunol. 164, 512–521 (2000).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Waldmann, H. The new immunosuppression: just kill the T cell. Nat Med 9, 1259–1260 (2003). https://doi.org/10.1038/nm1003-1259
Issue Date:
DOI: https://doi.org/10.1038/nm1003-1259
- Springer Nature America, Inc.
This article is cited by
-
Transplant tolerance: models, concepts and facts
Journal of Molecular Medicine (2006)